Table 3.
Summary of previous studies using different acceptable daily intake (ADI) values for the same pharmaceutical compound (Information about endpoints considered during estimation of ADI values are presented in parentheses).
| Pharmaceutical name | Webb et al. [12] (assumed body weight = 60 kg) | Schwab et al. [3] | Schulman et al. [11] (assumed body weight = 60 kg) | Christensen [7] |
|---|---|---|---|---|
| Acetylsalicylic acid | 8.3 μg/kg/d (30 mg/day therapeutic dose as anticoagulation therapy) | Not applicable | 16.67 μg/kg/d | Not applicable |
| Cyclophosphamide | 16.67 μg/kg/d (1 mg/d based on immunobullous skin disorders) | Not applicable | 0.017 μg/kg/d (1 μg/d based on no-significant-risk-level) | 0.01 μg/d (for rat) |
| Doxycycline | 3 μg/kg/d (100 mg/day therapeutic dose based on bacterial infection) | 30 μg/kg/d (value established from WHO representing antimicrobial sensitivity of human intestinal microflora) | Not applicable | Not applicable |
| Tetracycline | 3 μg/kg/d (1,000 mg/day therapeutic dose based on bacterial infection) | 30 μg/kg/d (value established from WHO representing antimicrobial sensitivity of human intestinal microflora) | Not applicable | Not applicable |
| Oxytetracycline | 3 μg/kg/d (1,000 mg/day therapeutic dose based on bacterial infection) | 30 μg/kg/d (value established from WHO representing antimicrobial sensitivity of human intestinal microflora) | Not applicable | Not applicable |
| 17α-ethinylestradiol | 0.167 μg/kg/d (0.010 mg/d therapeutic dose based on menopausal symptoms) | Not applicable | Not applicable | 6 μg/d (prepubescent boys) |
| Phenoxymethyl-penicillin | 16666 μg/kg/d (1,000 mg/day therapeutic dose based on bacterial infection) | Not applicable | Not applicable | 5.9 μg/d |
| Clofibrate | 8333 μg/kg/d (500 mg/d therapeutic dose based on hyperlipoproteinaemia) | Not applicable | 278 μg/kg/d | Not applicable |